title: Fenofibric acid for hyperlipidemia.
abstract: BACKGROUND
  3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (i.e., statins) are the mainstay of therapy for hyperlipidemia, as per the current National Cholesterol Education Program (NCEP) recommendation. However, the role of other agents, such as the fibrates, is continually being debated in the context of incremental risk reduction, especially in the setting of mixed dyslipidemia. Results from the ACCORD Trial have further added to the confusion. Fibrates also have a role to play in familial hyperlipidemias and in hypertriglyceridemia. Fenofibric acid is one of the newly approved forms of fenofibrate with enhanced bioavailability and was recently approved by the Food and Drug Administation (FDA) for the treatment of various types of hyperlipidemia, in conjunction with statins.
  
  
  METHODS
  This article reviews the role of fenofibric acid in the context of results from recent randomized trials on fenofibrate, including the ACCORD Trial. It discusses the current status of fenofibric acid in the management of dyslipidemia, especially in combination with statins, and also addresses the comparative efficacy and safety profile of this new molecule against other agents in its class.
  
  
  CONCLUSIONS
  Fenofibric acid in combination with low- to moderate-dose statins is an effective and safe option in the treatment of mixed dyslipidemia, although the long-term effects on cardiovascular risk reduction need to be explored further.
authors.affiliation: Department of Internal Medicine, Creighton University Medical Center, 601 N 30th Street, Suite 5850, Omaha, Nebraska 68131, USA.
authors.forename: Alok
authors.initials: A
authors.lastname: Saurav
authors.forename: Manu
authors.initials: M
authors.lastname: Kaushik
authors.forename: Syed M
authors.initials: SM
authors.lastname: Mohiuddin
mesh_terms: D011345:Fenofibrate / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000960:Hypolipidemic Agents; C006012:fenofibric acid; D011345:Fenofibrate